Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence.
作者信息
Xu Lingyu, Xu Yan
机构信息
Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, China.
出版信息
J Am Soc Nephrol. 2025 Feb 1;36(2):322-323. doi: 10.1681/ASN.0000000552. Epub 2024 Nov 15.
Abstract
摘要
相似文献
1
Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence.
J Am Soc Nephrol. 2025 Feb 1;36(2):322-323. doi: 10.1681/ASN.0000000552. Epub 2024 Nov 15.
2
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.
Diabetes Obes Metab. 2025 Aug;27(8):4311-4319. doi: 10.1111/dom.16468. Epub 2025 May 21.
3
Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence.
J Am Soc Nephrol. 2025 Feb 1;36(2):324. doi: 10.1681/ASN.0000000553. Epub 2024 Nov 15.
4
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.
J Am Soc Nephrol. 2024 Oct 1;35(10):1381-1390. doi: 10.1681/ASN.0000000000000436. Epub 2024 Jul 12.
5
The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
Nephrol Dial Transplant. 2023 Sep 29;38(10):2289-2297. doi: 10.1093/ndt/gfad078.
6
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
Diabetes Obes Metab. 2025 Aug;27(8):4415-4426. doi: 10.1111/dom.16478. Epub 2025 May 30.
7
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
Nephrol Dial Transplant. 2024 Feb 28;39(3):414-425. doi: 10.1093/ndt/gfad183.
8
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3.
9
Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial.
Nephrol Dial Transplant. 2025 Jul 7. doi: 10.1093/ndt/gfaf119.
10
Peripartum dapagliflozin improves late-life maternal cardiovascular outcomes in a murine model of superimposed preeclampsia.
Am J Obstet Gynecol. 2025 Mar 29. doi: 10.1016/j.ajog.2025.03.035.
引用本文的文献
1
Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence.
J Am Soc Nephrol. 2025 Feb 1;36(2):324. doi: 10.1681/ASN.0000000553. Epub 2024 Nov 15.
本文引用的文献
1
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.
J Am Soc Nephrol. 2024 Oct 1;35(10):1381-1390. doi: 10.1681/ASN.0000000000000436. Epub 2024 Jul 12.
2
Prioritising deteriorating patients using time-to-event analysis: prediction model development and internal-external validation.
Crit Care. 2024 Jul 17;28(1):247. doi: 10.1186/s13054-024-05021-y.
3
A flexible parametric accelerated failure time model and the extension to time-dependent acceleration factors.
Biostatistics. 2023 Jul 14;24(3):811-831. doi: 10.1093/biostatistics/kxac009.
4
Effects of Proportional Hazard Assumption on Variable Selection Methods for Censored Data.
Stat Biopharm Res. 2020;12(2):199-209. doi: 10.1080/19466315.2019.1694578. Epub 2019 Dec 23.
5
Competing Risks, Treatment Switching, and Informative Censoring.
JAMA Cardiol. 2021 Aug 1;6(8):871-873. doi: 10.1001/jamacardio.2021.1239.
6
Accelerated failure time models for semi-competing risks data in the presence of complex censoring.
Biometrics. 2017 Dec;73(4):1401-1412. doi: 10.1111/biom.12696. Epub 2017 Apr 10.
7
Score Estimating Equations from Embedded Likelihood Functions under Accelerated Failure Time Model.
J Am Stat Assoc. 2014 Oct;109(508):1625-1635. doi: 10.1080/01621459.2014.946034.
8
Testing the proportional hazards assumption in case-cohort analysis.
BMC Med Res Methodol. 2013 Jul 9;13:88. doi: 10.1186/1471-2288-13-88.
9
Censoring issues in survival analysis.
Annu Rev Public Health. 1997;18:83-104. doi: 10.1146/annurev.publhealth.18.1.83.
Zotero 插件